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To investigate the role of A2A adenosine receptors in adaptive
responses to chronic intermittent dopamine receptor stimula-
tion, we compared the behavioral sensitization elicited by re-
peated L-DOPA treatment in hemiparkinsonian wild-type (WT)
and A2A adenosine receptor knock-out (A2A KO) mice. Although
the unilateral nigrostriatal lesion produced by intrastriatal injec-
tion of 6-hydroxydopamine was indistinguishable between WT
and A2A KO mice, they developed strikingly different patterns of
behavioral sensitization after daily treatment with low doses of
L-DOPA for 3 weeks. WT mice initially displayed modest con-
tralateral rotational responses and then developed progres-
sively greater responses that reached a maximum within 1
week and persisted for the duration of the treatment. In con-
trast, any rotational behavioral sensitization in A2A KO mice was
transient and completely reversed within 2 weeks. Similarly, the
time to reach the peak rotation was progressively shortened in
WT mice but remained unchanged in A2A KO mice. Further-
more, daily L-DOPA treatment produced gradually sensitized
grooming in WT mice but failed to induce any sensitized groom-
ing in A2A KO mice. Finally, repeated L-DOPA treatment re-
versed the 6-OHDA-induced reduction of striatal dynorphin
mRNA in WT but not A2A KO mice, raising the possibility that
the A2A receptor may contribute to L-DOPA-induced behavioral
sensitization by facilitating adaptations within the dynorphin-
expressing striatonigral pathway. Together these results dem-
onstrate that the A2A receptor plays a critical role in the devel-
opment and particularly the persistence of behavioral
sensitization to repeated L-DOPA treatment. Furthermore, they
raise the possibility that the maladaptive dyskinetic responses
to chronic L-DOPA treatment in Parkinson’s disease may be
attenuated by A2A receptor inactivation.
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For 30 years the dopamine precursor L-DOPA has been the
most effective and commonly prescribed treatment for Parkin-
son’s disease (PD). Despite its considerable symptomatic motor
benefit, chronic administration of L-DOPA leads to abnormal
motor responses known as dyskinesias, involving involuntary cho-
reic or dystonic movements in50% of patients (5 years after the
initiation of the treatment) (Chase, 1998; Obeso et al., 2000).
Such shortcomings of L-DOPA and other dopaminergic drugs
have prompted a search for alternative treatment strategies that
provide symptomatic benefits while avoiding the delayed motor
complications associated with the long-term use of anti-
parkinsonian drugs. Several neurotransmitters have been impli-
cated in the motor complications elicited by repeated dopamine
receptor stimulation, including glutamate (Marin et al., 1996;
Tzschentke and Schmidt, 1998; Calabresi et al., 2000), cannabi-
noids (Souilhac et al., 1995; Zeng et al., 1999), opioids (Henry and
Brotchie, 1996), and adenosine (Richardson et al., 1997; Kanda et
al., 2000; Jenner, 2000). Recently, the A2A adenosine receptor has
emerged as an attractive target for PD treatment by virtue of its
concentrated expression in striatopallidal neurons and its modu-
lation of dopamine receptor-mediated functions (Schiffmann et
al., 1991; Fink et al., 1992; Ferre´ et al., 1997; Svenningsson et al.,
1999). In addition to the documented motor-activating feature of
A2A receptor antagonists (Richardson et al., 1997; Impagnatiello
et al., 2000), their minimal propensity for eliciting dyskinesia in
L-DOPA-primed nonhuman primates (Kanda et al., 1998;
Grondin et al., 1999) has further enhanced their therapeutic
potential in PD.
To critically evaluate the involvement of A2A receptors in
L-DOPA-induced dyskinesia, we have adopted a rodent “prim-
ing” model in which behavioral sensitization is elicited by re-
peated treatment with a low dose of L-DOPA in unilateral
6-hydroxydopamine (6-OHDA)-lesioned mice (Carey, 1991;
Henry et al., 1998). The delayed induction of markedly increased
contralateral rotation as well as several characteristic neurochem-
ical adaptations in this rodent model closely resemble several
behavioral and neurochemical features of L-DOPA-induced dys-
kinesia in parkinsonian nonhuman primates and in PD patients
(Brotchie, 1998; Henry et al., 1998). Thus, this behavioral sensi-
tization model may provide useful information on the maladap-
tive neuronal plasticity that underlies L-DOPA-induced dyskine-
sia in PD. We examined the effect of genetic inactivation of A2A
receptors on chronic L-DOPA-induced behavioral sensitization
using this rodent model of dyskinesia. Our genetic (knock-out)
approach to A2A receptor inactivation offers several advantages
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that complement standard pharmacological approaches, which
are hindered by intrinsic limitations of partial specificity and
efficacy. The results suggest that the A2A receptor is required for
the development and persistence of L-DOPA-induced behavioral
sensitization in mice.
MATERIALS AND METHODS
Breeding of A2A adenosine receptor knock-out mice
The A2A adenosine receptor knock-out (A2A KO) mouse line was gen-
erated in a pure 129-Steel genetic background as previously described
(Chen et al., 1999a) and was maintained for 3 years through breeding
by heterozygote intercrosses. For each of the present experiments, wild-
type (WT) and A2A KO littermates (both male and female) of the F4
generation were matched for gender, age (4–5 months), and body weight
(22–27 gm).
6-Hydroxydopamine lesions
All experiments were performed in accordance with Massachusetts Gen-
eral Hospital and National Institutes of Health Guidelines on the ethical
use of animals. They were maintained in “home” cages with a 24 hr 1:1
light /dark cycle. To produce unilateral striatal dopamine depletion, the
mice were pretreated with desipramine hydrochloride (25 mg/kg), to
minimize damage to noradrenergic neurons. Under Avertin (2% 2,2,2-
tribromoethanol and 1% amyl alcohol) anesthesia (20 ml/kg, i.p.), mice
were infused with 10 g of 6-OHDA (2.5 g/l in normal saline
containing 0.05% of ascorbic acid) delivered by a microinfusion pump (1
l /min) into the left dorsal striatum at the following coordinates (from
bregma: 1.1 mm anterior, 1.5 mm lateral, 2.0 mm ventral) (Franklin and
Paxinos, 1997).
Behavioral analysis
Behavioral analysis was performed by an observer, who was blinded to
the genotype of the animals. Seven days after 6-OHDA lesioning, the
WT and A2A KO mice (n  9–12) were randomly assigned to daily
treatment with either low doses of L-DOPA (1.0, 1.8, and 2.5 mg/kg) or
water for 3 weeks. All animals were pretreated with benserazide, a
peripheral decarboxylase inhibitor (2.0 mg/kg, i.p., 20 min before
L-DOPA or water injection). Contralateral rotation and grooming behav-
iors were evaluated in a test cage every other day from day 1 to day 14,
and every 2 d from day 15 to day 20. The intensity and kinetic profile of
L-DOPA-induced contralateral behavior was monitored, and recordings
were established by monitoring the number of complete (360°) rotations
ipsilateral and contralateral to the lesion in a 60 min testing period
immediately after the injection of L-DOPA or water. Stereotyped groom-
ing behavior was scored (in a 60 min test period immediately after the
injection) by the observer using the following scale: 0  inactive (mostly
motionless without stereotypies), 1  active without grooming (coordi-
nated movements/exploration without stereotypies), 2  mild grooming
(sporadic face washing and head stretching), 3  moderate grooming
(frequent but discontinuous face washing, rearing and standing with hind
limbs), 4  vigorous grooming (repetitive face and body washing in a
sequential chain of grooming activity), and 5  intensive grooming
(grooming of any kind with forepaws interspersed with vigorous groom-
ing of the hindflank or anogenital region).
Biochemical assessments
Striatal content of DA and DOPAC. In a separate experiment, 7 d after
6-OHDA injection, mice were killed by rapid cervical dislocation, and
their striata were dissected and assayed for catecholamines by standard
reverse-phase HPLC with electrochemical detection, as described previ-
ously (Chen et al., 2001).
Dopamine transporter binding autoradiography. Dopamine transporter
(DAT) binding was assessed using the radioligand [ 3H]-mazindol (spe-
cific activity  24 Ci/mmol; DuPont NEN, Boston, MA) in mice killed
1 week after 6-OHDA injection (and before any L-DOPA treatment) or
4 weeks after the 6-OHDA injection (i.e., 3 weeks after the first daily
L-DOPA treatment and 24 hr after the last L-DOPA treatment). Twenty
micrometer coronal sections at the levels of anterior, middle, and poste-
rior striatum were processed for [ 3H]-mazindol binding as previously
described (Chen et al., 2001). Specific striatal [ 3H]-mazindol binding
(femtomoles per milligram of tissue) was calculated by subtracting non-
specific binding (in the presence of 100 M unlabeled nomifensine) from
total binding.
In situ hybridization histochemistry. In situ hybridization histochemistry
with cRNA probes was performed according to protocols described in
previous studies (Moratalla et al., 1996a,b). Mouse brain sections were
post-fixed in buffered 4% paraformaldehyde, acetylated in acetic anhy-
dride, and dehydrated in graded ethanol. Sections were hybridized with
a 35S-labeled RNA probe (150,000 cpm/l buffer) specific for the rat
prodynorphin cDNA (provided by J. Douglass) (Civelli et al., 1985) in a
hybridization buffer described previously (Moratalla et al., 1996a,b).
After hybridization, sections were washed and then treated with RNase
A (100 g/ml), and washed again to final strength in 0.1 SSC at 70°C for
30 min. The slides were rinsed, dried, and exposed to BioMax MR films
(Amersham Biosciences, Arlington Heights, IL) for 15–20 d.
Image analysis. Optical densities on the film were determined using a
computing densitometer equipped with an image analysis program (mod-
el 300A; Molecular Dynamics, Sunnyvale, CA). Approximately three or
four sections through the striatum, at rostral and middle levels, were
analyzed for each mouse. For each section, dynorphin mRNA levels were
determined by optical densities that were in the 6-OHDA lesioned side
(left) and the contralateral side (right). Dynorphin mRNA levels from
6-OHDA lesioned side were expressed as a percentage of the contralat-
eral (unlesioned) side because previous experiments have demonstrated
that a unilateral 6-OHDA lesion did not alter dynorphin mRNA expres-
sion in the contralateral striatum (Cenci et al., 1993).
Statistical analysis
All data are expressed as group mean  SEM and analyzed using “SAS”
or “SPSS” statistical programs. The significance of differences between
two genotypes across multiple treatment groups was evaluated by split-
plot ANOVA for repeated measures followed by Fisher’s least significant
difference (LSD) comparison test. The significance of differences be-
tween responses on treatment day 1 and subsequent treatment days was
evaluated by one-way ANOVA for repeated measures, followed by Dun-
nett’s test. Selective comparison of specific treatment day versus day 1
was evaluated by the randomization test for matched pairs (Siegel and
Castellan, 2000). Grooming behavioral data were analyzed by the non-
parametric Kruskal–Wallis test followed by the Mann–Whitney U test.
The differences in dynorphin mRNA levels between WT and KO groups
were analyzed by Student’s t test.
RESULTS
Intrastriatal 6-OHDA injection produced
indistinguishable dopaminergic neurotoxicity in WT
and A2A KO mice
Previous studies in our laboratory and others showed that inac-
tivation of A2A receptors by either genetic ablation or pharma-
cological blockade protects against brain injuries induced by
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Chen et
al., 2001), kainic acid (Jones et al., 1998a,b), or middle cerebral
artery occlusion (Monopoli et al., 1998; Chen et al., 1999a).
Accordingly, we first determined whether the dopaminergic le-
sion induced by 6-OHDA differs between A2A KO and WT mice.
The administration of 6-OHDA into the left striatum of mice
significantly reduced striatal levels of dopamine as well as its main
metabolite 3,4-dihydroxyphenylacetic acid (DOPAC) ipsilateral
to the lesion (Table 1). These reductions were indistinguishable
between WT and A2A KO mice.
The extent of the lesion was also assessed by determining the
DAT binding density in striatum before and after chronic
L-DOPA treatment. Seven days after the unilateral 6-OHDA
injection, striatal DAT binding density decreased significantly in
the ipsilateral striatum of L-DOPA-naive mice (Table 1). Consis-
tent with the dopamine content data, the reduction of DAT
binding on the ipsilateral side was virtually identical between WT
and A2A KO groups (Table 1). Similarly, in the mice treated with
L-DOPA daily for 3 weeks, no difference in the reduction of
ipsilateral DAT density was found between the two genotypes.
There was also no difference between KO and WT mice with
respect to the slight rise in contralateral DAT binding density
observed after the repeated L-DOPA treatments. [The basis for
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this rise is unclear, although a similar elevation in DAT binding
density in unlesioned striatum after repeated L-DOPA treatment
has been reported by others (Ikawa et al., 1993).] Thus, these
results confirm that the intrastriatal injection of 6-OHDA pro-
duced similar dopaminergic neurotoxicity, setting the stage for a
meaningful comparison of behavioral sensitization in hemipar-
kinsonian WT and A2A KO mice. These data also indicate that
the neuroprotective effect of A2A receptor inactivation against
MPTP toxicity (Chen et al., 2001) does not necessarily apply to
all models of PD.
Lack of persistent rotational sensitization to chronic
L-DOPA treatment in hemiparkinsonian A2A KO mice
To evaluate A2A receptor involvement in L-DOPA-induced be-
havioral sensitization, we treated WT and A2A KO mice with 20
daily doses of L-DOPA beginning 1 week after unilateral intra-
striatal injection of 6-OHDA. L-DOPA at the very low dose of 1.0
mg/kg, intraperitoneally, did not result in any significant con-
tralateral or ipsilateral turning behavior in either WT and A2A
KO mice (Fig. 1A) as compared with the vehicle-treated group in
which only a weak net ipsilateral response (8  1 and 5  5 net
ipsilateral turns/hr on day 1 in WT and A2A KO mice, respec-
tively) could be seen consistently throughout the test period (data
not shown). However, the administration of L-DOPA at higher
but still modest doses 1.8 and 2.5 mg/kg produced a marked
behavioral sensitization in WT mice (Fig. 1B,C, respectively).
Specifically, after a lag time of 3 d, mice treated daily with 1.8
mg/kg L-DOPA began to develop an increased contralateral ro-
tational response that reached a maximum by day 9 (Fig. 1B). In
WT mice the sensitized response persisted unabated for the
duration of the 20 d treatment period. However, the behavioral
pattern induced by repeated L-DOPA treatment in A2A KO mice
markedly differed from that in WT mice (Fig. 1B) (F(8,160) 2.92;
p  0.01; split-plot ANOVA). Although A2A KO mice displayed
a trend of gradual enhancement of contralateral rotations reach-
ing an apparent maximum between days 5 and 9 of daily 1.8
mg/kg L-DOPA treatment, they failed to develop statistically
significant behavioral sensitization at this dosage (one-way
ANOVA for repeated measurements; n 12; F(8,99) 1.677; p
0.118). Most strikingly, any enhancement of rotational response
to L-DOPA in A2A KO mice was not maintained after day 9.
Instead, by day 14 the response to L-DOPA had returned to
baseline (i.e., that on day 1) where it remained for the rest of the
experiment. As previously noted and discussed, acute dopami-
nergic stimulation of motor activity (as on day 1) is not enhanced
in A2A KO mice, in contrast to the demonstrated potentiating
effect of A2A antagonists on motor activity (Chen et al., 2000).
Because A2A KO mice primarily failed to develop significantly
sensitized rotational behavior, the possibility arose that using this
low dose of L-DOPA (1.8 mg/kg) a “threshold” response needed
to elicit sustained behavioral sensitization was reached in WT but
not KO mice. Indeed, the acute motor response to dopaminergic
stimulation (e.g., on day 1) (Fig. 1B) may have been slightly lower
in A2A KO than in WT mice (as we and others have previously
observed; Ledent et al., 1997; Chen et al., 2000). To address this
possibility we attempted to overcome such a threshold effect by
examining the influence of A2A receptor inactivation on the
duration of sensitization induced by a higher dose of L-DOPA. As
shown in the Figure 1C, 2.5 mg/kg L-DOPA produced substan-
tially greater contralateral turning (compared with 1.8 mg/kg
daily) for both the initial and maximal response, with the latter
occurring earlier (by day 7) using the higher dose, in both WT
and A2A KO mice. Nevertheless, the rotational sensitization was
again maintained for the duration of daily L-DOPA treatment
only in WT mice. By contrast, the response to this higher dose of
L-DOPA in A2A KO mice, after apparently sensitizing with a peak
on day 5 ( p  0.05 only for day 5 compared with day 1 by the
randomization test for matched pairs, and p  0.05 by one-way
ANOVA for repeated measurements), reverted by day 17 to that
observed on day 1. Note that the absence of persistent sensitiza-
tion in KO mice was as prominent at 2.5 mg/kg as it was at 1.8
mg/kg L-DOPA, although their peak rotational responses at the
higher dose exceeded the peak responses observed in WT mice at
the lower dose. Thus, these data confirm the effect of A2A recep-
tor inactivation on the development and particularly the mainte-
nance of L-DOPA-induced rotational sensitization and rule out
the possibility that it can be explained by nonspecific subthreshold
responses to L-DOPA in A2A KO mice.
Because development of L-DOPA-induced behavioral sensiti-
zation is associated with a progressively shortened onset and
duration of action, we also compared how the kinetics of
L-DOPA-induced responses changed over the 3 week course of
daily treatments in WT and A2A KO mice. As shown in Figure
2A, the time to reach the peak contralateral turning response to
a single dose of L-DOPA (1.8 mg/kg) was progressively shortened
in WT mice (from 20–30 min on day 1, to 20 min on day 11, to 10
min on day 20). In contrast, the time to reach the peak response
in A2A KO animals remained virtually unchanged throughout the
treatment (20 min for days 1, 11 and 20). Moreover, the number
Table 1. Neurochemical and autoradiographic measures of nigrostriatal innervation in WT and A2A KO mice after a unilateral 6-OHDA lesion
Genotype
DA DOPAC
DAT density
(optical densities  100)
(pm/mg tissue) Naive Sensitized
Wild-type
Ipsilateral 15  3* 1.2  0.2* 154  15* 163  21*
Contralateral 61  1 4.0  0.2 285  27 407  16
A2A KO
Ipsilateral 12  3* 1.0  0.2* 161  19* 165  20*
Contralateral 60  2 3.5  0.3 289  35 415  18
DA and DOPAC were determined in striatal homogenates obtained from WT and A2A KO animals naive to L-DOPA treatment and killed 1 week after the injection of
6-OHDA. Striatal DAT densities were determined using tissue samples obtained before (naive) and after 3 weeks (sensitized) of intraperitoneal 2.5 mg/kg L-DOPA treatment.
*p  0.05 versus respective contralateral side.
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of contralateral rotations occurring over the initial 10 min after
L-DOPA administration increased steadily and significantly in
WT but not A2A KO mice from day 1 to day 20 (Fig. 2B). These
results further support an important role for the A2A receptor in
the adaptive behavioral responses to chronic L-DOPA treatment.
Lack of sensitized grooming responses to chronic
L-DOPA in hemiparkinsonian A2A KO mice
We also examined the effect of A2A receptor inactivation on
chronic L-DOPA-induced grooming behaviors. Grooming is by its
nature a stereotyped behavior, and it has been proposed to share
Figure 1. Effect of A2A receptor deficiency on dose-dependent L-DOPA-
induced behavioral sensitization in hemiparkinsonian mice. WT (black
squares) and A2A KO ( gray circles) mice were treated with benserazide (2
mg/kg, i.p.) plus L-DOPA at intraperitoneal doses of 1.0 mg/kg (A; n 10
per each genotype), 1.8 mg/kg (B; n 10 WT mice and n 12 KO mice),
or 2.5 mg/kg (C; n  10 per each genotype) once a day for 20 d.
Contralateral rotational behavior was evaluated for the 1 hr test period
immediately after the administration of L-DOPA on the indicated days.
Data are expressed as mean  SEM of the net contralateral rotations
(contralateral minus ipsilateral turns). For B, F(8,160)  2.92, *p  0.01
compared with the corresponding KO value (split-plot ANOVA followed
by Fisher’s LSD comparison test); for C, F(8,135)2.32, *p  0.05 com-
pared with the corresponding KO value (split-plot ANOVA followed by
Fisher’s LSD comparison test).
Figure 2. Peak rotational response to L-DOPA occurs progressively
earlier in hemiparkinsonian WT but not A2A KO mice. A shows the initial,
midway, and final time courses for turning induced by the daily intraperi-
toneal administration of 1.8 mg/kg L-DOPA in WT and A2A KO mice,
i.e., on the 1st (shaded circles), 11th ( filled triangles), and 20th (shaded
squares) day of 20 consecutive daily L-DOPA treatments. B (replotted
from the 10 min time points in A) depicts the progressive increase in
contralateral rotations for the initial 10 min after L-DOPA adminis-
tration from the 1st to the 11th to the 20th day in WT mice
(F(2,40)7.32; *p  0.01; split-plot ANOVA followed by Fisher’s LSD
test) but not in A2A KO mice.
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common neurochemical features with L-DOPA-induced dyskine-
sia in primates (Graybiel et al., 2000). Daily treatment with
vehicle did not induce any significant grooming behavior in WT
and KO mice of 129-Steel genetic background (most average
scores were 1, n  2 for WT and n  3 for KO mice, respec-
tively; data not shown). However, daily L-DOPA administration
to WT mice (Fig. 3) increased the frequency and intensity of
grooming after repeated challenges, reaching its maximum after
11 d at the lowest dose tested (1.0 mg/kg) (Fig. 3A) or 9 d using
the intermediate dose (1.8 mg/kg) (Fig. 3B) (n 10–12; p 0.05;
Kruskal–Wallis test followed by Mann–Whitney U test). Groom-
ing responses then remained enhanced throughout the duration
of treatment (Fig. 3). In A2A KO mice, by contrast, the grooming
responses to either of these daily doses of L-DOPA showed no
significant sensitization over the entire 3 week period (Fig. 3)
(n  10–12). Thus, chronic L-DOPA-induced sensitization of
grooming behavior in WT but not in KO mice provides evidence
for A2A receptor involvement in L-DOPA-induced sensitization
of stereotyped as well as rotational behaviors.
Daily L-DOPA reverses the reduction in dynorphin
expression induced by 6-OHDA in WT but not A2A
KO mice
Finally, we also examined the effect of A2A receptor inactivation
on chronic L-DOPA-induced striatal neuronal activity using
dynorphin mRNA as a cellular readout. Dynorphin mRNA is
predominantly coexpressed with D1 dopamine receptor mRNA in
striatonigral neurons (the “direct” pathway) (Gerfen et al., 1990;
Le Moine et al., 1990). The L-DOPA-induced reversal of the
6-OHDA-induced reduction in dynorphin mRNA has been asso-
ciated with the development of L-DOPA-induced dyskinesia in
parkinsonian animals (Andersson et al., 1999; Jenner, 2000). In
situ hybridization analysis shows that 6-OHDA lesioning reduced
dynorphin mRNA levels in the ipsilateral striatum of both WT
and KO mice. Consistent with previous reports (Andersson et al.,
1999; Henry et al., 1999; Pirker et al., 2001), chronic treatment
with L-DOPA dose-dependently reverses the 6-OHDA-induced
reduction in dynorphin mRNA to normal levels in WT mice (Fig.
4) (n  8–9; p  0.05; compared with contralateral striatum,
paired Student’s t test). L-DOPA did not, however, increase
dynorphin mRNA above normal levels in WT mice (as others
have observed; Andersson et al., 1999; Henry et al., 1999), prob-
ably because of the particularly low doses of L-DOPA tested here
(1.0–2.5 mg/kg, threefold less than in the otherwise similar stud-
ies). In contrast, chronic L-DOPA treatment failed to reverse the
reduction in dynorphin mRNA to normal levels in A2A KO mice
(Fig. 4). Thus, the A2A receptor may contribute to the altered
neuronal activity of the “direct” striatonigral pathway that is
associated chronic L-DOPA-induced behavioral changes.
Figure 3. Sensitization of DOPA-induced grooming behavior is attenu-
ated in mice lacking adenosine A2A receptors. Grooming activity, defined
as maximal grooming score recorded over the 1 hr testing period, was
determined in WT (black squares) and A2A KO ( gray circles) animals
receiving an intraperitoneal dose of 1.0 mg/kg (A) or 1.8 mg/kg (B)
L-DOPA. Data are expressed as mean  SEM of 10–12 animals. *p 
0.05; compared with the corresponding KO value; Kruskal–Wallis test
followed by Mann–Whitney U test.
Figure 4. Daily L-DOPA reverses the reduction in dynorphin expression
induced by 6-OHDA in WT but not A2A KO mice. The dynorphin mRNA
levels were determined by in situ hybridization histochemistry in mice
unilaterally lesioned with 6-OHDA, followed by daily treatment with
L-DOPA (1.8 or 2.5 mg/kg) or vehicle for 21 d. Dynorphin mRNA levels
[optical density (OD)] were quantified at the level of midstriatum and
expressed as a percentage of the contralateral side (unlesioned striatum).
Chronic treatment with L-DOPA reverses the 6-OHDA-induced reduc-
tion in dynorphin mRNA to normal levels in WT but not A2A KO mice
(*p  0.05; Student’s t test compared with the corresponding WT group).
The numbers inside the bars indicate the animal numbers for each group.
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DISCUSSION
The A2A adenosine receptor is required for
L-DOPA-induced behavioral sensitization
The main finding of our study is that genetic inactivation of A2A
receptors abolished sustained behavioral sensitization in re-
sponse to repeated L-DOPA treatment in mice. Our results clearly
show that WT mice developed progressively enhanced contralat-
eral rotational, whereas A2A KO mice developed only a trend
toward L-DOPA-induced sensitization of rotational responses
that appeared milder than in WT mice and primarily failed to
reach statistical significance. The time to reach peak rotation
progressively shortened in WT but not A2A KO mice. In keeping
with the lack of sustained rotational behavioral sensitization, A2A
receptor inactivation also prevented or markedly reduced the
induction of grooming responses. These altered behavioral re-
sponses were further substantiated by the neurochemical finding
that repeated L-DOPA treatment reversed the 6-OHDA-induced
reduction of striatal dynorphin mRNA levels in WT but not A2A
KO mice. Thus, the absence of chronic L-DOPA-induced sensi-
tization at the behavioral (contralateral rotation and grooming)
and cellular (dynorphin mRNA) levels in hemiparkinsonian mice
lacking A2A receptors strongly suggests that A2A receptors are
required for L-DOPA-induced behavioral sensitization.
The most striking finding of the present study is that 6-OHDA-
lesioned mice lacking the A2A receptors do not maintain sensi-
tized rotational motor responses to repeated L-DOPA adminis-
tration. Although the maintenance of behavioral sensitization,
like its induction and expression, is recognized as a mechanisti-
cally discrete phase (Wolf, 1998; Chase and Oh, 2000; Li et al.,
2000; Vanderschuren and Kalivas, 2000), relatively little is known
about the unique molecular pathways leading to the persistence
of this phenomenon, which can last for months or years under
some circumstances (Robinson and Becker, 1986). The present
data indicate that A2A receptors may play a critical role in the
maintenance of L-DOPA-induced motor sensitization. Thus, they
suggest that endogenous adenosine acting on (presumably stria-
tal) A2A receptors may facilitate the long-term adaptive changes
induced by chronic L-DOPA exposure.
The reversal of an apparent sensitization to L-DOPA (Fig.
1B,C) in the absence of functional A2A receptors could be ex-
plained by the rapid development of tolerance. This consideration
is prompted by the well documented phenomenon of tolerance to
the motor effects of the nonspecific adenosine receptor antagonist
caffeine (for review, see Fredholm et al., 1999). However, several
studies have now shown that the motor activation induced by a
specific A2A receptor antagonist shows no tolerance after chronic
intermittent administration (Halldner et al., 2000; Pinna et al.,
2001). Moreover, in a preliminary study the locomotor response
to self-administered intravenous cocaine showed no tolerance in
A2A KO mice, in contrast to the marked tolerance that develops
in their WT littermates (Rocha et al., 2001). Therefore, tolerance
is unlikely to account for a reversal of newly developed sensiti-
zation in A2A KO mice. The absence of active A2A receptor-
mediated maintenance of the adaptive changes underlying sensi-
tization may offer a better explanation.
The absence of sustained sensitization to repeated L-DOPA
treatment in mice lacking the A2A receptor likely reflects a
broader phenotype of attenuated adaptive motor responses to
intermittent dopaminergic stimulation. Indeed, we have found
that the robust locomotor sensitization to the indirect dopamine
agonist amphetamine in WT mice is completely absent in their
A2A KO littermates (Chen et al., 1999b). In line with these
findings, a withdrawal syndrome that develops after chronic re-
peated alcohol administration was attenuated in mice lacking the
A2A receptor and in mice treated with the specific A2A antagonist
ZM 241385 (El Yacoubi et al., 2001). However, the extent to
which acute pharmacological blockade of the A2A receptor par-
allels the A2A KO phenotype in preventing sensitized responses
to chronic dopaminergic stimulation remains to be clarified. For
example, although one study has raised the possibility that
L-DOPA-induced motor sensitization may be prevented by paired
exposure to a specific A2A antagonist (Pinna et al., 2001), another
has suggested that a specific A2A agonist can have the same effect
on methamphetamine-induced motor sensitization (Shimazoe et
al., 2000). Nevertheless when taken together, A2A receptor studies
based on either pharmacological or genetic approaches have
consistently pointed to an important role for this receptor in
adaptive motor behaviors.
Potential mechanisms by which the A2A receptor
facilitates L-DOPA-induced behavioral sensitization
Considerable research effort has been devoted to clarifying the
anatomical and neurochemical basis of sensitized behavioral re-
sponses to dopaminergic stimuli. Although this phenomenon has
been well localized to the mesolimbic and nigrostriatal dopami-
nergic systems of the basal ganglia, less is clear about the specific
dopaminergic receptor subtypes, as well as the other neurotrans-
mitters and the intracellular signaling cascades mediating these
adaptive changes (Pierce and Kalivas, 1997). Both D1- and D2-
like receptors have been implicated in L-DOPA-induced sensiti-
zation (Morelli and Di Chiara, 1987; Blanchet et al., 1995, Bordet
et al., 2000). Activation of A2A receptors has been shown to
antagonize D2 receptor-mediated neurotransmitter release,
immediate-early gene expression, and psychomotor stimulation
(Ferre´ et al., 1997; Svenningsson et al., 1999). Thus, the A2A
receptor may modulate L-DOPA-induced behavioral sensitization
through its cellular-level interaction with the D2 receptor in
striatopallidal neurons (of the “indirect” pathway), which express
both A2A and D2 receptors. Within striatal neurons multiple
intracellular signaling cascades, the cAMP pathway in particular,
have also been implicated in the basal ganglia plasticity that
underlies sensitization to dopaminergic stimulation (Chase and
Oh, 2000; Jenner, 2000). For example, repeated treatment with
L-DOPA or other dopaminergic stimuli has been shown to en-
hance phosphorylation and activation of cAMP pathway targets,
including dopamine- and cAMP-dependent phosphoprotein
(DARPP-32) and cAMP-response element binding protein and
expression of the long half-life transcription factor FosB (Barone
et al., 1994; Moratalla et al., 1996a; Pierce and Kalivas, 1997;
Chase and Oh, 2000; Dunah et al., 2000). The A2A receptor,
which is positively coupled to adenylate cyclase and cAMP pro-
duction through Gs (Svenningsson et al., 1999), may affect
L-DOPA-induced neurochemical and behavioral changes by in-
fluencing this pathway. In this regard, a recent study shows that
D2 receptor blockade induces phosphorylation of DARPP-32
protein in WT but not A2A KO mice, indicating a critical role for
A2A receptors in striatal cellular signaling involving the cAMP
pathway (Svenningsson et al., 2000). Further studies are needed
to clarify the exact role of cAMP signaling in the A2A receptor-
mediated modulation of behavioral sensitization.
The A2A receptor may also exert its effect on behavioral sen-
sitization through a network-level interaction with D1 receptors,
which are primarily expressed on non-A2A receptor-expressing
Fredduzzi et al. • A2A Receptors in L-DOPA Sensitization J. Neurosci., February 1, 2002, 22(3):1054–1062 1059
striatonigral neurons (of the “direct” pathway). Interestingly,
Pollack et al. (1997) showed that “priming” by the dopamine
agonist apomorphine leads to the recruitment of D2 receptor-
expressing in concert with D1 receptor-expressing striatal neu-
rons to produce enhanced behavioral and cellular responses.
Similarly, in striatal slices, activation of the D2 or A2A receptors
transynaptically interacts with D1 receptors to modulate phos-
phorylation of DARPP-32, an effect that was blocked by tetrodo-
toxin (Lindskog et al., 1999). These studies illustrate clearly a
functional cross-talk between the indirect pathway (coexpressing
A2A and D2 receptors) and the direct pathway (expressing D1
receptors) at the network level. Furthermore, in striatonigral
neurons of the “direct” pathway, the increased expression of
mRNAs encoding neuropeptides substance P and dynorphin has
been associated with the development of behavioral sensitization
in response to repeated L-DOPA (Engber et al., 1991; Herrero et
al., 1995; Cenci et al., 1998; Andersson et al., 1999; Pirker et al.,
2001), indicating overactivity of the (D1-expressing) “direct”
pathway in L-DOPA-sensitized animals. Our finding that chronic
L-DOPA treatment reverses the 6-OHDA-induced reduction in
striatal dynorphin mRNA in WT but A2A KO mice supports this
notion. It is also consistent with our preliminary finding that D1
agonist challenge after the chronic L-DOPA treatment schedule
used in this study resulted in enhanced contralateral turning
(compared with baseline rotational response to D1 stimulation
before L-DOPA treatments) in WT but not A2A KO mice (S.
Fredduzzi, M. A. Schwarzschild, and J.-F. Chen, unpublished
observations). Thus, A2A receptor modulation of dopaminergic
sensitization may involve both D1 and D2 dopamine receptors in
the “direct” striatonigral and “indirect” striatopallidal pathways,
respectively.
Finally, A2A receptors may modulate L-DOPA-induced behav-
ioral sensitization by modulating presynaptic release of several
neurotransmitters such as dopamine, glutamate, and GABA, all
critically involved in the development of dopamine-associated
behavioral sensitization (Pierce and Kalivas, 1997). Although
activation of A1 receptors at presynaptic terminals markedly inhib-
its the release of a wide-range of neurotransmitters, activation of
A2A receptors has been shown to enhance dopamine release in
striatum and nucleus accumbens (Okada et al., 1996; Sebastiao and
Ribeiro, 1996). This is further supported by the recent demonstra-
tion that basal dopamine levels in striatum, measured by microdi-
alysis, were significantly lower in A2A KO mice than that of WT
littermates (Dassesse et al., 2001), and is consistent with our
findings that depolarization-elicited dopamine release was signifi-
cantly attenuated in striatal synaptosomes from A2A KO mice (T.
Turner, J.-F. Chen, and M. A. Schwarzschild, unpublished obser-
vations). Thus, inactivation of A2A receptors may reduce dopamine
release resulting in hypo-dopaminergic activity, and in turn, atten-
uated L-DOPA sensitization.
In addition to dopamine, glutamate and its release from nerve
terminals in the striatum, nucleus accumbens, and ventral mes-
encephalon have been strongly implicated in the different phases
of sensitization (for review, see Wolf, 1998). A2A receptors serve
a well established excitatory CNS role (Sebastiao and Ribeiro,
1996) attributed to their facilitative effects on glutamate release,
which have been demonstrated in striatum (Popoli et al., 1995) as
well as cortex (O’Regan et al., 1992) Thus, an attenuation of
glutamate release in A2A KO mice may contribute to their phe-
notype of attenuated L-DOPA-induced sensitization. Alterna-
tively, A2A receptor-enhancement of GABA release particularly
from A2A receptor-expressing striatopallidal neurons (Kurokawa
et al., 1994; Mayfield et al., 1996) also offers a plausible basis for
the reduced L-DOPA sensitization in KO mice. Modulation of
striatal acetylcholine (as well as dopamine) release by A2A recep-
tors (Zetterstrom and Fillenz, 1990; Kurokawa et al., 1994, 1996)
are also potential targets of A2A receptors involvement.
Therapeutic implications for PD
The lack of persistent L-DOPA-induced behavioral sensitization
in A2A KO mice has implications for the development of A2A
antagonists as a potential therapeutic intervention for PD and
psychiatric disorders associated with dopaminergic system dys-
function. A2A antagonists are being developed as novel therapeu-
tic agents for PD treatment based primarily on their well docu-
mented capacity to enhance motor function. In animal models of
PD, A2A antagonists alone or in combination with L-DOPA
reverse parkinsonian motor deficits in rodents and nonhuman
primates (Richardson et al., 1997; Kanda et al., 1998; Grondin et
al., 1999). In addition, we have recently demonstrated that A2A
antagonists attenuate dopaminergic neurotoxicity in the MPTP
model of PD in mice, raising the possibility that A2A antagonists
may offer neuroprotective as well as symptomatic benefits in PD
treatment (Chen et al., 2001). The present findings suggest an
additional potential benefit of A2A receptor inactivation as ad-
junctive therapy with L-DOPA in PD. Persistent rotational sensi-
tization and grooming sensitization induced by repeated L-DOPA
administration was dependent after the presence of the A2A
receptor, and thus A2A antagonists may attenuate the maladap-
tive dyskinetic responses to chronic L-DOPA treatment in PD.
Together, these multiple potential therapeutic benefits of A2A
antagonists (motor enhancement, neuroprotection against dopa-
minergic toxicity, and the prevention of dyskinesia), coupled with
their low risk of CNS side effects (given the relatively discrete
striatal expression of the A2A receptor) should greatly encourage
their development as a promising treatment for PD. The first
clinical trials to evaluate a specific A2A antagonist are now tar-
geting advanced PD patients suffering from dyskinesias and re-
lated motor fluctuations. This strategy is supported the preclinical
evidence that A2A receptor blockade may enhance motor func-
tion without inducing or exacerbating dyskinesias (Kanda et al.,
1998; Grondin et al., 1999). However, the new findings suggesting
additional benefits of attenuated dyskinesia development and
disease progression in PD provide a strong rationale for consid-
ering the use of A2A antagonists early in the course of the disease.
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